Schering AG of Germany says it is confident of meeting its net profitand sales targets for 2001, expecting a strong fourth quarter to make up for underperformance in the second and third reporting periods. Klaus Pohle, the firm's chief financial officer, told Reuters that he still expected net earnings to rise 15%-20% this year, while sales should climb 9%-10%. Operating profit is forecast to increase 3%.
"We expect sales in the second and third quarters to lie below target, while they will be stronger in the fourth quarter," Mr Pohle said, adding that this confidence is based on the impact of new product launches in the USA before the end of the year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze